|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||189.84 - 191.72|
|52 Week Range||153.50 - 194.27|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.44%|
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
On February 26, 2018, Stryker (SYK) closed trading at $165.77. According to Stryker, it has delivered sales growth consistently higher than that of the average performance of the medical technology industry over the past several years. The stock is currently trading above its 200-day moving average of $160.03 and its 50-day moving average of $160.03.
What's Next for Abbott Laboratories after a Stellar 2017?The impact of 4Q17 earnings release on ABT’s stock price performance
Stryker's 52-Week High: Should You Expect Further Upside?SYK stock at 52-week high On January 9, Stryker (SYK) traded at a 52-week high of $164.2 per share. The stock ended trading with a closing price of $160.4. As of January 9, 2018, SYK stock is trading higher than its 50-day moving average of $155 as well as the 200-day moving average of $148.1. Stryker traded at a 52-week low of $117.6 on January 9, 2017. The company’s one-year stock return is ~35% as of January 9, 2018.
On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock's 50-day moving average stands at $221.22.
The repeal of the tax deduction for high medical expenses may reduce the number of taxpayers opting for costly medical technologies and services.
If someone had told you at the beginning of the year that the Republican-controlled Congress was going to try and fail to repeal and replace the Affordable Care Act (ACA) multiple times during 2017, you probably wouldn’t have believed them. You might think that this uncertainty would have taken a bearish toll on healthcare stocks, but you’d be wrong in most cases. Many healthcare stocks are keeping pace with, or outperforming, the S&P 500.